Strategic Advisory on Sustainability Compliance: A Pharmaceutical Company
Background
A Danish company operating at the intersection of biotechnology and pharmaceuticals, specializing in preclinical research and drug discovery. With a strong commitment to sustainability, the company integrates environmental and social responsibility into its core operations.
In addition to offering advanced services in vivo models, experimental research, and data analytics to support the development of new treatments, the company allocates 10% of its profits towards the green transition, aiming to drive positive environmental and social impact.
Our role
We conducted a thorough gap analysis of the company’s nature-based investment model. Our team focused on assessing the structure of Carbon Credit programs in relation to their climate impact, while also examining their self-acquiring land model for nature protection as an alternative to purchasing Carbon Credits. Through this analysis, we identified key gaps in terms of cost, nature impact, and measurement methodologies.
Leveraging our findings, we provided strategic guidance on how the company could integrate these investments and insights into their sustainability reporting, with a particular emphasis on GHG reporting and broader environmental impact assessment.
Output
- Outlined an overview of the regulatory landscape within the sustainability agenda.
- Identification of GHG requirements for investments in the land use, land use change, and forestry sector.
- A comprehensive GHG report prepared for audit, with results tested by an audit firm.
- Utilization of a technical platform to visualize the impact of their forest investment, along with strategic advice on navigating carbon offsets versus direct climate contributions.
More from Sustainability advisory
We are ready to help you
